vernakalant Articles
Merck & Co returns vernakalant rights to Cardiome
27 September 2012
Merck & Co drops development of oral vernakalant
20 March 2012
US cardiologists attitudes to vernakalant and ranolazine Rxing
6 February 2012
Showing 1-4 of 4 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Italy's pharma market slump set to continue, warns GlobalData
- Pfizer to split-off remaining 80% interest in Zoetis
